1. Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis;Khoury;JAMA Netw Open,2022
2. The road towards polyclonal anti-SARS-CoV-2 immunoglobulins (hyperimmune serum) for passive immunization in COVID19;Focosi;Life (Basel, Switz),2021
3. What is the optimal usage of Covid-19 convalescent plasma donations;Focosi;Clin Micro Infect,2020
4. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma;Vandeberg;Transfusion,2021
5. Polizzotto M.N., Nordwall J., Babiker A.G., Phillips A., Vock D.M., Eriobu N., et al. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. The Lancet.